<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007379</url>
  </required_header>
  <id_info>
    <org_study_id>CARMA-2101</org_study_id>
    <nct_id>NCT05007379</nct_id>
  </id_info>
  <brief_title>Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids</brief_title>
  <acronym>CARMA</acronym>
  <official_title>Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cell-based immune therapy using modified macrophages is a promising therapeutic approach in&#xD;
      breast cancer. The objective of this cohort study is to collect tumor samples to develop&#xD;
      patients' derived organoids to test the antitumor activity of newly developed&#xD;
      CAR-macrophages. Other biological samples will be collected such as blood to analyze the host&#xD;
      inflammatory status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity of the CAR-macrophages compared to non-modified macrophages</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This is a cohort study conducted in breast cancer patients requiring a surgery or a tumor&#xD;
        biopsy as part of their care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 years or more&#xD;
&#xD;
          -  Histologically confirmed breast cancer at any stage&#xD;
&#xD;
          -  Requiring surgery or tumor biopsy as standard of care&#xD;
&#xD;
          -  Any or no systemic treatment&#xD;
&#xD;
          -  Signed informaed consent&#xD;
&#xD;
          -  Health insurance coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposed to biospecimen collection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nawale HAJJAJI, MD PhD</last_name>
    <phone>+33 320295910</phone>
    <email>n-hajjaji@o-lambret.fr</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

